Can a Patient's own immune cells be engineered to fight a rare sarcoma?

NCT ID NCT07104682

Ongoing ⭐️ CURE ⭐️ Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial tests a personalized cell therapy called GCAR1 in a single patient with metastatic alveolar soft part sarcoma (ASPS) that has relapsed and cannot be surgically removed. The therapy uses the patient's own immune cells, engineered to recognize and attack cancer cells displaying a specific protein. The goal is to see if this treatment is safe and can shrink or control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GCAR1, a personalized cell therapy made from the patient's own immune cells (T-cells) engineered to recognize and attack cancer cells that carry a protein called GPNMB.
What this could lead to: If successful, this approach could offer a new treatment option for alveolar soft part sarcoma, a rare cancer with limited therapies.
What could go wrong: This is an early, single-patient study, so results may not apply to others. CAR T-cell therapy can cause severe side effects, and the treatment may not shrink the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA (ASPS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALVEOLAR SOFT PART SARCOMA (ASPS) SARCOMA

Contacts and locations

Locations

University of Calgary

Calgary, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.